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Skin biopsies and scale extracts from 22 patients with 
psoriasis were examined for the presence of chemotactic 
lipoxygenase products of arachidonate metabolism. 
Heat-stable leukocyte chemotactic activity in aqueous 
extracts of 2-mm punch biopsies from involved and un-
involved patient skin was significantly elevated, com-
pared to healed psoriatic skin and to skin of normal 
controls. Ether extracts (pH 3.0) from 13 mg of psoriatic 
scales contained a mean chemotactic activity corre-
sponding to that of leukotriene B4, 5 x 10-s M. On 
reverse phase high-pressure liquid chromatography, the 
main chemotactic lipids in scale extracts were leuko-
triene B,, and 5-HETE. Since lipoxygenase products are 
potent mediators of inflammation, they may play an 
important role in the evolution and maintenance of pso-
riatic lesions. 
Psoriasis is a localized or generali zed inflammatory derma-
tosis of unknown etiology which is characterized by increased 
epidermal cell turnover wi t h associated scaling of the lesional 
skin . Emigration of leukocytes into lesional dermis and epider-
mis has been observed to be an early event in the evolution of 
psoriatic plaques (1] . For this reason, chemotactic factors have 
been searched for in psoriatic lesions, and complement frag-
ments (2] as well as a derivative of arachidonic acid (aa), 12-
hydroxy-5,8,10,14-eicosatetraenoic acid (1 2-HETE) [3], have 
been identified in scales and skin biopsies of psoriasis lesions 
in the past. 
Recently, 5(S),12(R)-dihydroxy-6,8,10,14-eicosatetraenoic 
acid (5,12-di -HETE or leukot riene B., [LTB.]) has been shown 
to be generated by the action of a 5-lipoxygenase on aa [4) . 
This substance is as powerful a chemoattractant as C5a, is 
more potent than the mono-HETE derivatives o.f aa [?,6], and 
induces the directed migration of neut rophils, eosmophils, mon-
ocytes, and fibroblasts [5- 9). 
In the present investigation , we have examined extracts of 
whole skin and of scales from patients with psoriasis for t he 
presence of aa-derived chemotactic factors, using their biologic, 
physical, and chemical properties for identi fication. The data 
show that increased quantities of chemotactic lipoxygenase 
products are present in lesional and normal-appearing psoriatic 
skin and in psoriatic scales. 
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MATERIALS AND METHODS 
Patients hospi ta lized because of severe psorias is se rved as subjects. 
Two-millimeter punch biopsies were performed on 15 patients from 
clinically involved and uninvolved skin of the trunk, immediately after 
local injection of Xylocai ne. Biopsies were a lso taken from healed skin 
les ions of 8 patients after top ical anth ralin t herapy and from 8 healthy 
voluntee rs. T he skin biopsies were placed in 300 Ill Hanks' buffer, 
boiled ooo·c. 10 min) in order to destroy nonleukotriene chemoat-
t ract.ants such as C5a [7] and in hibito rs of t he chemoattract.ants [10, 
11] . This procedure increases the yield of chemotactic activity from 
biologic materia l a nd genera lly reduces t he biologic activi ty of synthetic 
LTB, by not more than 20%. Aliquots (100 pi) of the supernatants 
were tested in the chemotaxis assay. 
Scales from 22 untreated patients were obtained by scraping the 
psoriatic les ions with a wooden applicator. Shavings from the callus of 
the feet of 9 normal volunteers served as controls. The dried scales and 
callus were weighed, suspended in Hanks' buffer (G ibco, Glasgow, 
U.K.) , homogenized with a Potter-E lvehjem device, and adjusted to pH 
3.0 with 0.5 N HCI. Three mi lliliters of buffer, conta ining 80 mg scales, 
was extracted 3 times into 2 volumes of ether (Roth , Karlsruhe, F.R. G.) . 
After evaporation of t he ether phase in a rotating evaporator, t he 
samples were reconstituted in 3 ml Hanks ' buffer, t he pH of the ether 
and aqueous extracts was adjusted to 7.4, and 500-1'1 a liquots were 
tested in the chemotax is assay. 
Chemotaxis was measured in modified Boyden chambers, wit h Fi-
coll -separated human neut rophils as target cells, as previously de-
scribed [1 2). LTB, (Dr. E. J . Corey, Boston, Massachusetts) served as 
control chemoattractant in each experiment. Resul ts a re expressed as 
percent of t he chemotactic activity of 10- 7 M L TB,. 
Reverse phase high-pressure liquid chromatography (H PLC) was 
performed with a Spectra Physics model SP 8100 and an SP 4100 UV-
VIS detector, adjusted to 280 nm for measuring prostaglandjn B2 
(PGB2l and the 5,12,-di -HETEs, and to 232 nm for the monohydroxy 
derivatives of aa. Al iquots of the ether extracts (pH 3.0) of scales tha t 
had been test.ed during chemotax is were evaporated, resuspended in 
met hanol:water 69:3 1, adjusted to pH 5.7 with acetic acid, and eluted 
in t he same solvent at 1 ml/mi n from a Li Chrosorb RP-18 (5 I'm ) 
column (4 X 250 mm) (E. Merck, Darmstadt, F.R.G.). PGB2 (Sigma, 
Munich, F.R.G .), 15-HETE, 12- HETE, 5-HETE (RAN Biochemicals, 
Is rael) , L TB4 , 20-0H L TB,, and 20-COO H LTB, (k indly donated by 
Dr. J. Rokach, Montreal, Canada) served as marker molecules. Chem-
otactic activity in fractions of column eluates was measured aft er 
evaporation a nd reconstitution of the samples in Ha nks' buffer. 
Statist ical evaluation was done with the Student t-test, using a 2-
way hypothesis and unpaired data. Resu lts a re expressed as mean 
±so. 
RESULTS 
Fig 1 shows t he neut rophil chemotactic activity in the heated 
aqueous extracts of a ll the biopsies from involved, healed, and 
uninvolved patient skin and from normal volunteers. There 
was an increased activity in involved and uninvolved patient 
sk in , compared to healed skin and to sk in of normal volunteers 
( P < 0.05) , even though the variations from patient to patient 
were ma rked, as is evident from the large standard deviation. 
After successful t herapy and regression of t he cutaneous in -
fl ammation, t he values returned to levels close to t hose in 
normal control subjects. 
In order to obtain larger quantities of material from psoriat ic 
skin for analytic studies, psoriatic scales were examined as a 
possible source of chemotactic lipoxygenase products. T he 
chemotactic activity measured in organic and aqueous sca le 
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extracts from 22 different patients is shown in Fig 2, together 
with that in 9 normal persons' callus extracts. All the biologic 
activity partitioned into the organic phase, while barely any 
activity was noted in t he aqueous phase or in either phase of 
extracts from normal callus (p ::,; 0.05) . The maximal chemo-
tactic activities measured in the psoriatic scale extracts corre-
sponded to the chemotactic activity of 5 X w-R M L TB., 
standard/13 mg scale(= 500 1!1 scale supernatant). There were 
again wide quantitative variations in the biologic activ ity of 
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F IG 1. Scattergram of chemotactic act ivity (% of 10- 7 M LTB,) , 
measured in 100 1'1 of a 300-1'1 boiled extract of punch biopsies from 
involved, uninvolved (n = 15), involved healed (n = 8) skin of patients, 
and from skin of normal control s (n = 8). Differences between samples 
prior to treatment and after healing were significant (p "" 0.05). The 
same held for the differences between untreated patient skin and the 
skin of normal contro ls (p "" 0.001 ). 
70 
60 
50 
~ 
'o ~0 
~ 
en 
1-
__j 
30 
<F. 
- 20 u 
<t 
E 
"' .c. (.) 10 
' 
• 
I 
• 
• 
• 
•• 
•• 
I 
org . 
• 
aqu. or g. oqu . 
psoriatic scales normal callus 
F IG 2. Scattergram or chemotactic activity (% of w-7 M LTB,) , 
measured in organic and aqueous sca le extracts (n = 22) of patients 
with psorias is. Data obtained with extracts from callus of normal 
controls (n = 9) are shown for comparison. 
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extracts from different patients (see large SD) which could not 
be related to type and severity of the lesions from which the 
scales were obtained. 
The chemotactic act ivity in the organic phase extracts was 
furt her characterized as being heat stable at 100°C, 10 min. 
When freshly generated zymosan-activated serum was ex-
tracted into ether at pH 3.0, the chemotactic activity remained 
in the aqueous phase, and this activity was destroyed by heating 
(not shown) . 
On reverse phase HPLC of the scale extracts, peaks were 
noted in 9 of the 10 different samples studied, at the marker 
positions for L TB.,, 15-HETE, 12-HETE, and 5-RETE. Two 
examples of such elut ion curves are shown in Fig 3a,b. As can 
be seen by comparing these two curves, t here can be wide 
variations from patient to patient with regard to quantity and 
type of e luted lipids. A number of t he early peaks and of the 
peaks t hat appeared at 232 nm in Fig 3b could not be identified. 
Chemotactic activity was measured in the HPLC eluates at the 
position of the L TB., peak and its 20-0H and 20-COOH me-
taboli tes. Rarely, there was a lso low- level activity with the 5-
HETE peak. Chemotactic peaks were not identified in the 
eluates of normal callus, as would be expected from the findings 
with the bioassay (Fig 2). 
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F'I(: 3. Reverse phase HPLC elution pro(ile of orga nic scale (80 mg) 
ex tracts from 2 psoriasis patients. PGB2 (reLention time 8 min) had 
been added t.o the sample in (a) as a marker. Peaks were noted at the 
marker position for the co mpounds shown, and several nonidentdied 
peaks were observed as well. The chemotactic activ ity in the eluates at 
the LTB, peak (a) co rresponded to an activ ity of 5 X 10-9 M of the 
L TB, sta ndard. Additional chemotactic activity was found at the 
marker position for 20-0H L TB.,, 20-COOH L'I'B, and for 5-HETE in 
the eluate shown in (b) . Abso rbance (ordi nate) is in arbitrary units and 
therefore not. shown. 
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DISCUSSION 
In this report several lines of evidence a re presented which 
show that chemotactic activity derived from lipoxygenase prod-
ucts of aa metabolism can be identified in whole psoriatic skin 
and in the scales overlying involved sk in. In t he first set of 
experiments, heated aqueous extracts from biopsies of unin-
volved and involved psoriatic skin are shown to contain neu-
trophil chemotactic activity (Fig 1). After topical treatment of 
t h e skin with anthralin, thi s activity has returned to almost 
baseline levels in extracts of biopsies from previously involved 
skin . Whole skin extracts from normal contro ls contain signif-
icantly less activity than those of diseased subjects (Fig 1). The 
heat stabili ty of t he chemotactic principle in these aqueous 
extracts of psoriatic skin biopsies suggests t hat chemoattrac-
tants other than C5a are present [7] . 
This assumption was further supported when it was found 
that psoriatic scales, after extraction into ether at low pH, also 
contained significant ly elevated levels of chemotactic activity, 
compared to callus from normal controls, a property that is not 
shared by complement-derived chemoattractants (see Results). 
Finally, the presence of chemotactic lipoxygenase products was 
confirmed by reverse phase HPLC (Fig 3). Chemotactic activity 
was found most consisten t ly with L TB. which is t he most 
potent among t he aa-derived chemoattractants [5,6] and less 
so at the marker positions of its weaker oxidation products at 
the 20-carbon position (13]. T he peaks at the positions of the 
markers for the mono-HETEs contained no chemotactic activ-
ity except for some occasiona l low activity with 5-HETE. 
In our assay system, LTB.1 is 100- 1000 times more potent 
than 5-HETE (7], which fits with data from the li te rature 
where 5-HETE is agai n the most potent among the mono-
HETEs (14]. On reverse phase HPLC, chemotactically inactive 
isomers might elute at the same position as L TB.1. While we 
have not provided conclusive proof of t he chemic&! nature of 
t he chemotactic activi ty measured at 280 nm on reverse phase 
HPLC, t he lack of biologic activity of the isomers makes it 
likely that L TB.1 a nd its metabolites are t he most important 
lipid chemoattractants in t he scale extracts. Other factors 
might modulate its activity, t he mono-HETEs by their additive 
or synergistic interaction with L TB. , and heat- labile factors by 
thei r inhibitory activity (10,11] . Quantitative differences in the 
complex interplay between these stimulatory and inhibitory 
components t hat might a lso be related to age and type of the 
psoriatic lesion, could explain the great patient to patient 
variabili ty of the biologic activity in the crude extracts. 
The observation that chemotactic activity is elevated in 
biopsies of nonlesional sk in during the active stage of the 
disease, is intrigu ing (Fig 1). It suggests that the increased 
generation of t he lipid mediators is an early event in t he 
evolution of psoriatic lesion and that the basic defect in pso-
riatic skin is not confined to the lesional sk in . Since inflam-
matory leukocytes are lacking in uninvolved psoriatic skin , one 
must postulate t hat the lipoxygenase products derive from 
resident macrophages or from keratinocytes which are also able 
to generate these mediators [15] . On the other hand, the obser-
vation that lipoxygenase-dependent mediators are elevated in 
uninvolved skin does not necessarily imply t hat t heir increased 
production is the primary pathogenetic event in psoriasis. 
Our data are in agreement with the obse rvatio ns of Michel 
eta! [ 16] who measured increased levels of other aa metabolites 
such as PGE~ and PGF2" in uninvolved psoriatic skin . Ham-
marstrom et a l [3] noted, on t he other hand, that 12-HETE 
was elevated in involved skin only. These divergent results with 
regard to aa metabolites in normal -appearing psoriatic skin 
may be related to the type of mediator measured or to variations 
in the severity of disease among t he patient groups studied. 
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From the data presented here, it remains uncertain which 
ce ll type is responsible for the production of aa metabolites in 
the psoriatic skin. Resident and infiltrating leukocytes as well 
as epidermal cells themselves might be t he source of the lipid 
chemoattractants in whole skin and scales. From their location 
in the epidermis, t hese potent mediators of inflammation would 
t~en perpetua~e the inflammatory process in the underlying 
tiss.ue. They m1ght a lso down-regulate the immune response by 
t he!f recently discovered abili ty to induce suppressor T lym-
phocytes [17]. 
The potential significance of leukotrienes in t he pathoO"enesis 
and therapy of psoriasis has become a focus of intense i~terest 
[18,19]. We have preliminary evidence that these compounds 
are also presen_t in several other inflammatory a nd scaling 
dermato.ses. TillS sugge.sts that a lthough the leukotrienes may 
play an 1mportant role 111 the development and maintenance of 
psoriatic lesions, their activity is neither disease-initiatin O" nor 
disease-specific. " 
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